secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001193125-23-205557
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres reports Q2 2023 net income of $46.6M on $125M VOWST milestone; early launch demand strong
--------------------------------------------------------------------------------

- Net income $46.6M vs net loss $64.7M YoY; $125M milestone from Nestlé upon FDA approval of VOWST.
- VOWST net sales $1.6M in first partial quarter; 610 prescription forms, 282 patient starts from 480+ HCPs.
- Cash $229.5M; new $250M Oaktree debt facility, drew $110M at close, $53.4M to retire prior debt.
- SER-155 Phase 1b Cohort 1: favorable tolerability, reduced ESKAPE pathogen domination; Cohort 2 data mid-2024.
- R&D expense $46.8M, G&A $28.1M; VOWST commercial mfg costs to capitalize post-approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312523205557/0001193125-23-205557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312523205557/d541674d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-205557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer